AVLN Avalyn Pharma Inc.: institutional ownership and insider trading
99 funds reported holding $1.46B of Avalyn Pharma Inc. in their latest 13F filings; in Q2 2026 funds net bought $1.46B, with 93 new positions and 0 funds selling out; over the last 12 months insiders bought $25.0M and sold $0 on the open market.
AVLN revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$28.9M, EPS -0.98
- Quarter ended Mar 31, 2026: revenue n/a, net income −$26.9M, EPS -21.83
- Quarter ended Jun 30, 2025: revenue n/a, net income −$20.2M, EPS -17.63
- Quarter ended Mar 31, 2025: revenue n/a, net income −$17.5M, EPS -63.24
Famous investors holding AVLN
- Ken Griffin (Citadel Advisors): $31.6M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $757K, 0.0% of the portfolio
- George Soros (Soros Fund Management): $329K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $220K, 0.0% of the portfolio
Largest institutional holders of AVLN
- FMR LLC — $192M
- Novo Holdings A/S — $128M
- SR ONE CAPITAL MANAGEMENT, LP — $109M
- PERCEPTIVE ADVISORS LLC — $88.1M
- SUVRETTA CAPITAL MANAGEMENT, LLC — $82.4M
- NVP Associates, LLC — $74.7M
- WELLINGTON MANAGEMENT GROUP LLP — $72.5M
- PRICE T ROWE ASSOCIATES INC /MD/ — $57.1M
- Catalio Capital Management, LP — $55.2M
- T. Rowe Price Investment Management, Inc. — $52.8M
Recent AVLN insider trades
- May 1, 2026: Novo Holdings A/S bought 555,555 shares ($10.00M)
- May 1, 2026: Carroll Jill bought 277,778 shares ($5.00M)
- May 1, 2026: George Simeon bought 555,555 shares ($10.00M)
5%+ owners
- FMR LLC: 13.2% (Schedule 13G/A, filed Aug 6, 2026)
- Novo Holdings A/S: 8.8% (Schedule 13G, filed Aug 14, 2026)
- SR One Capital Management, LLC: 7.5% (Schedule 13D, filed May 8, 2026)
- Perceptive Advisors LLC: 6.0% (Schedule 13G, filed May 7, 2026)
- SUVRETTA CAPITAL MANAGEMENT, LLC: 5.6% (Schedule 13D, filed May 8, 2026)
- Norwest Venture Partners XV, LP: 5.1% (Schedule 13G, filed Aug 11, 2026)